|
Bao
Hua Sun, Jun Zhang, Bao Jü Wang, Xi Ping Zhao, You Kun Wang,Zhi Qun Yu,Dong
Liang Yang and Lian Jie Hao Department
of Clinical Immunology, Tongji Hospital, Tongji Medical University,
Wuhan 430030, Hubei Province, China
Dr. Bao Hua Sun, graduated from the Department of Pathology of
Tongji Medical University in 1997, Postdoctor, currently engaged in
apoptosis research
of hepatocellular carcinoma, having 17 papers published.
Correspondence to: Dr. Dong Liang Yang, Department of
Clinical Immunology, Tongji Hospital, Tongji Medical University,
Wuhan 430030, Hubei Province, China
Telephone:
0086-27-83662570
Email. bhsun@yahoo.com
Received:
2000-01-01
Accepted: 2000-01-15
Subject
headings: carcinoma, hepatocellular;
caspase 3; apopto
sis; liver neoplasms; gene
expression
Sun BH, Zhang J, Wang BJ, Zhao XP, Wang YK, Yu ZQ, Yang DL, Hao
LJ.Analysis of in vivo patterns of caspase 3 gene expression in
primary hepatocellular carcinoma and its relationship to p21WAF1
expression and hepatic apoptosis. World
J Gastroentero, 2000;6(3):356-360
Abstract
AIM: To detect the expression
of caspase 3 gene in primary huma
n hepatocellular carcinoma (HCC) and investigate its relationship to
p21WAF1 gene expression and HCC apoptosis.
METHODS: In situ hybridization was employed to
determine caspase 3 and p21WAF1 expression in HCC. In
situ end-labeling was used to detect hepatocytic apoptosis in
HCC.
RESULTS: Twenty-one of 39 (53.8%) cases of HCC were found to
express caspase 3 transcripts, while 46.2% of HCC failed to express
caspase 3. Non-cancerous adjacent liver tissues showed more positive
caspase 3 (87.5%, 7/8) as compared with HCC (P<0.05).
The expression of caspase 3 is correlated with HCC differentiation,
72.2% (13/18) of moderately to highly differentiated HCC showed
caspase 3 transcripts positive, while only 38.1% of poorly
differentiated HCC harbored caspase 3 transcripts (P<0.05).
No relationship was found between caspase 3 expression and tumor
size or grade or metastasis, although 62.5% (5/8) of HCC with
metastasis were caspase 3 positive and a little higher than that
with no metastasis (51.6%, P>0.05).
Expression of caspase 3 alone did not affect the apoptosis index
(AI) of HCC. The AI was 7.12‰ in caspase 3-positive tumors (n=21),
while in caspase 3-negative cases (n=18) 6.59‰ (P>0.05).
Expression of caspase 3 clearly segregated with p21WAF1
positive tumors as compared with p21WAF1 negative cases
(16 of 23, 69.6% versus 5 of 16, 31.3%) with statistical
significance(P=0.017). In the cases with positive caspase 3
and negative p21WAF1 , the AI was found slightly higher,
but with no stati
stical significance, than that with expression of p21WAF1
and caspase
3 (7.21‰ vs 6.98‰, P>0.05).
CONCLUSION: Loss of caspase 3 expression may contribute to
HCC carcinogenesis, although the expression of caspase 3 does not
correlate well with cell apoptosis in HCC. p21WAF1 may be
merely one of the inhibitors which can reduce caspase 3 mediated
cell apoptosis in HCCs.
INTRODUCTION
Hepatocellular carcinoma(HCC), represent 80%-90% of the primary
liver cancer,
is one of the leading causes of cancer morbidity and mortality on a
global scale. More than 80% of liver cancer cases occurr in the
developing world, especially in China, where HCC is the second cause
of cancer death and responsib
le for 130000 deaths every year[1]. Despite dramatic
advances in
basic and clinical research in the past decades, the exact molecular
mechanism
for hepatocarcinogenesis is unclear. Gene expression changes have
been demonstrated in accordance with cell growth, differentiation
and carcinogenesis[2]. Tumor formation can result from a
decrease in cell death, as well a
s an increase in cell proliferation.In addition to altered
expression of cell cycle-related gene, dysregulation
of apoptosis (programmed cell death) is thought to contribute to
cancer by aberr
antly extending cell viability and favoring the accumulation of
transforming mut
ations[3].
Caspase
is a large family which contains at least 14 members. It has been
shown that caspase play an important role in regulating cancer cell
death both induced by activated lymphocytes through Fas/FasL pathway
and by chemotherapy agents[4]. Caspase 3 or cpp32 is the
key member of effector caspases. Caspase 3 had overexpression in
B-cell chronic lymphocytic leukemia (B-CLL)[5], acute
myelogenous leukemia (AML)[6], follicular small cleaved
cell non-Hodgkin’s B-cell lymphomas[7,8]
, human breast cancer cell lines and primary breast tumors[9]and
neurob
lastomas[10]. Caspase 3 is a potent protease which can
cleave a large
scale of substrate, including cell cycle related genes such as p21WAF1[4].
p21WAF1 is a cyclin-dependent kinase inhibitor and plays
an important role in DNA damage induced growth arrest. p21WAF1
overexpression can cause G1 cell cycle arrest and further
interrupt the apopto
tic process at a point upstream from caspase 3 activation[11].
In this study, we investigated the expression of caspase 3 in
primary human HCC and its potential impact on tumor cell apoptosis
and its relationship to p21WAF1 expression.
MATERIALS AND METHODS
Patients and samples
The surgically resected specimens employed in this study
were obtained from cons
ecutive patients with primary HCC who had undergone potentially
curative tumor resection at the Department of General and
Hepato-Biliary Surgery, Tongji Hospi
tal during 1996-1997. A cohort of 39 cases was involved in this
study. All cases
were selected on the basis of availability of frozen material for
study and on
the absence of extensive chemotherapy-induced tumor necrosis.
Materials were co
mposed of 3 cases of grade Ⅰ,
18 cases of grade Ⅱ,
11 cases of grade Ⅲ,
th
e remaining 7 cases were grade Ⅳ
according to TNM system (1987). The tumor lesions analyzed here
included 21 poor, 9 moderate and 9 well differentiations.
There were 34 males and 5 females, and the age ranged from 24 to 71
years with
an average of 46.1 (SD, 12.5). Eight cases of non
-cancerous adjacent liver tissues were also included in the study.
Routinely pr
ocessed 40g/L paraformaldehyde-fixed, paraffin-embedded blocks cont
aining principal tumor were selected. Serial sections of 5μm
were prepared from the cut surface of blocks at the maximum
cross-section of the tumor.
In situ hybridization staining for caspase 3 and p21WAF1and
scoring methods for its expression
The plasmid pET21b-cpp32 containing caspase 3 (cpp32) cDNA
probe was kindly provided by Dr. JC. Reed(La Jolla, USA). After
digestion with XhoⅠ
and NdeⅠ,
the fragment was separated by electrophoresis through an agar
ose gel and recovered by QIA quick gel extraction kit (QIAGEN) using
a micro-centrifuge according to the manufacturer’s protocol. The
p21WAF1 cDNA
probe was kindly provided by Dr. SJ Elledge (Houston, USA).
Preparation of p21WAF1 probe was described previously[12].
The probes were labeled and detected using a Dig DNA labeling and
detection kit (Boehringer Mannheim Biochemica, Germany). Briefly,
40g/L paraformaldehyde-fixed paraffin embedded samples were cut at 5μm
and adhered to APES-treated slides. After deparaffinized and
rehydrated through a graded s
eries of ethanol, the sections were immersed in a 0.01mol/L DEPC-treated
PBS (pH 7.4) two times each for 5min, and then, in PBS containing
100mmol/L glycine and PBS containing 3mL/L Triton X-100 for 5min in
turns. Sections were permeabilized for 30min at 37℃
with TE buffer (100mmol/L Tris-HCl, 50mmol/L EDTA, pH 8.0)
containing 10mg/L RNase-free proteinase K and washed with DEPC-treated
PBS, then incubated at 42℃
for 2h with pre-hybridization buffer. Hybridization solution
(400mL/L deionized formamide, 500g/L dextra sulfate, 1×Dehardt’s
reagent, 4×SSC,10mmol/L DTT, 1g/L yeast tRNA, 1g/L denatured salmon
sperm DNA) containing 2mg/L
probe overlay each section after deprive prehybr
idization buffer from slides and hybridize at 42℃for
36h in a humid chamb
er. The sections were washed in a shaking water bath at 37℃
in 2×SSC, 1×SSC,
0.1×SSC for 15min each, then washed with buffer Ⅰ
(100mmol/L Tris-HCl, pH 7.5, 150mmol/L NaCl) for 20min and with
blocking solution (buffer Ⅰ
containing 20mL/L normal sheep serum) for 30min, and added sheep
anti-Dig-alkaline phosphates (diluted at 1∶800
in bufferⅠ)
and incubated for another 1h before development by NBT at 37℃
for 3
h in the dark. Hybridization buffer containing no probe was used for
negativ
e control for each staining. Scoring method for caspase 3 and p21WAF1
expression was described by Kawasaki[13]. Positive tumor
cells were quantified by two independent observers, and the average
percentage of positive tumor cells was determined in at least 5
areas at ×400 and assigned to one of five categories: (a) 0, <1%;
(b)1,1%-25%; (c)2, 25%-50%; (d) 3,50%-75% and (e)4, >75%.
The ISH staining intensity was scored as (a) weak 1+; (b) moderate,
2+; and intense, 3+. For tumors showing heterogeneous staining, the
predomin
ant pattern was taken into account for scoring. The percentage of
positive tumor cells and staining intensity were multiplied to
produce a weighted score for each case. Cases with weighted scores <1
were defined as negative, otherwise were defined as positive.
Histochemical detection of apoptosis and determination of the
AI
Tumor cell apoptosis was identified by DNA fragmentation
detection kit (QIA33-kit, Calbiochem). Briefly, deparaffinized and
rehydrated sections were permeated with proteinase K(20mg/L in
10mmol/L Tris, pH 8.0) for 20min at room temperature and washed with
1×TBS (20mmol/L
Tris pH 7.6, 140mmol/L NaCl). After endogenous peroxidases were
inactivated by using 30mL/L hydrogen peroxide for 5min and washed
with 1×TBS, equilibration buffer was added to each section and
incubated at room temperature for 20min. Terminal deoxynucleotidyl
transferase (TDT) enzyme in TDT labeling reaction mix at a 1∶20
dilution was pipetted onto the secti
ons, followed by 1.5h incubation at 37℃.
After the reaction was termina
ted by immersing sections into stop solution and washed with
blocking buffer for 10min at room temperature, the anti-digoxingenin-peroxidase
was added to t
he sections. DAB solution was used for color development. Sections
were counters
tained by methyl green. A positive control generated covering
specimen with DNase Ⅰ
(1mg/L) for the first procedure. Specific positive tissue sections
were used for negative control by substituting distilled water for
the TDT in the reaction mixture. The AI was expressed as the ratio
of positively stained tumor cells and bodies to
all tumor cells, given a percentage for each case. A minimum of 1000
cells was counted under a 400-fold magnification. Positively
staining tumor cells with morphological characteristics of apoptosis
were identified using standard criter
ia, including chromatin condensation, nuclear disintegration and
formation of crescentic caps of condensed chromatin at the nuclear
periphery.
Statistical analysis
Variables associated with caspase 3 expression as well as
the relationship betwe
en caspase 3 and p21WAF1 were analyzed by χ2
test. Differences in the tumor cell AI for groups dichotomized
according to caspase 3 expression were checked by independent t
test.
RESULTS
Expression of caspase 3 gene in HCCs
By ISH staining, caspase 3 transcripts was detected
predominantly in cytoplasm (Figure 1). Consistent with the presence
of caspase 3 protein in human biopsy liver samples, expression of
caspase 3 in non-cancerous adjacent liver tissue was also observed
in 87.5% (7/8) of cases. The intensity of caspase 3 staining was
heterogeneous within a case detected. The tumor cells positively
stained by ISH range from 10% to 90%, depending on the cases examine
d. After multiplying the weighted caspase 3 score, 21 cases of HCC
in the present study were defined as positive (53.8%), with weighted
caspase 3 score from 1 to 12.
The expression of caspase 3 and its association with
clinicopathologica
l variables
A clinicopathological analysis of caspase 3 positive cases
is shown in Table 1. No statistical significance was observed in the
prognostic parameters, including tumor size, metastasis, TNM grade,
analyzed in the present study except for differentiation. The
expression of caspase 3 is correlated with HCC differ
entiation. It was found that as high as 72.2% (13/18) of moderately
to highly differentiated HCC showed caspase 3 transcripts positive,
while only 38.
1% of poorly differentiated HCC harbored caspase 3 transcripts (P<0.05).
Relationship between caspase 3 and p21WAF1
Twenty-three cases were detected expression p21WAF1
transcripts. Pos
itive signal was predominantly located in cytoplasm with a
heterogeneous distrib
ution of positive tumor cells. The significance of p21WAF1
gene expres
sion was discussed in our previous study[12]. Expression
of caspase 3 cl
early segregated with p21WAF1 positive tumors as compared
with p2
1WAF1 negative cases (16 of 23, 69.6% vs 5 of 16, 31.3% )
with statistical significance (P<0.05).
Table 1 Correlation between clinicopathological parameters and
expre
ssion of caspase 3 in HCCs
|
|
No.
|
Caspase
3 expression (%)
|
P
|
|
Samples
|
|
|
|
|
Non-cancerous
adjacent liver
|
8
|
7(87.5)
|
<0.05
|
|
HCC
|
39
|
21(53.8)
|
|
|
Age(year)
|
|
|
|
|
<60
|
28
|
15(53.6)
|
NS
|
|
>60
|
11
|
6(54.5)
|
|
|
Sex
|
|
|
|
|
Male
|
34
|
18(52.9)
|
NS
|
|
Female
|
5
|
3(60.0)
|
|
|
Tumor
size (cm)
|
|
|
|
|
>5.0
|
27
|
15(55.6)
|
NS
|
|
<5.0
|
12
|
6(50.0)
|
|
|
Differentiation
|
|
|
|
|
Well-moderate
|
18
|
13(72.2)
|
<0.05
|
|
Poor
|
21
|
8(38.1)
|
|
|
TNM
grade
|
|
|
|
|
Ⅰ-Ⅱ
|
21
|
12(57.1)
|
NS
|
|
Ⅲ-Ⅳ
|
18
|
9(50.0)
|
|
|
Metastasis
|
|
|
|
|
Negative
|
31
|
16(51.6)
|
NS
|
|
Positive
|
8
|
5(62.5)
|
|
|
p21WAF1
|
|
|
|
|
Positive
|
23
|
16(69.6)
|
<0.05
|
|
Negative
|
16
|
5(31.3)
|
|
NS:
no statistic significance
Figure 1 Caspase
3 transcripts were detected predo
minantly in cytoplasm by ISH (×200)
Figure 2 Apoptotic
cells were determined by criteria as
described in materials and methods.
Arrow shows fragmented nucleus (×200)
Relationship between tumor cell apoptosis and caspase 3
expression
Apoptotic cells and apoptotic bodies were found in all cases
of HCCs examined by in situ end-labeling (Figure 2). The mean
AI of all tumors
cases was 6.82‰ (s, 3.36‰; range 0.87‰-17.3‰). No
significant associ
ation was observed between AI and tumor stage. The mean AI for
caspase 3-positi
ve tumors (n=21) was 7.12‰ (s, 3.75‰), while in caspase
3-negative
cases (n=18) the AI was 6.59‰ (s, 2.98‰), no statistical
significanc
e was found between the two groups (P>0.05).
In the cases with co- ex
pression of p21WAF1 and caspase 3, the AI was found
lower, but with no significance, than that of cases with positive
caspase 3 and negative
p21WAF1 (6.98‰ vs 7.21‰).
DISCUSSION
In this study, we have shown that caspase 3 was expressed in
most of HCC cases.
In our opinion, we are the first to describe the cpp32 expression in
human prima
ry HCCs. Like the result of human biopsy and autopsy liver materials[14]
, the non-cancerous adjacent liver tissue showed strong caspase 3
expression. A
s high as 46.2% of human primary HCCs failed to show caspase 3
expression. In t
he 21 cases which express caspase 3, the expression showed
heterogeneous pattern
with a weighted score from 1 to 12. Because caspase 3 is the
effector caspase in the apoptosis pathways, we think that loss of
caspase 3 expression may play
an important role in HCC carcinogenesis. Caspase 3 expression had no
relationsh
ip with clinicopathological features except for tumor
differentiation (Table 1).
The result suggest that the expression of caspase 3 is correlated
with tumor differentiation in HCC. It was reported that 33.1% cases
of gastric carcinoma were caspase 3 positive[7]. Two of 3
breast carcinoma tissues expressed caspase 3, the immunointensity
was generally higher in
invasive cancers[8]. It raised the possibility that
expression of casap
se 3 in tumors showed tissue specificity. It was observed in this
study that the
apoptosis index (AI) was not associated with the expression of
caspase 3 in HCC
(7.12‰ in cpp32-positive cases versus 6.59‰ in cpp32-negative
group).In the non-cancerous adjacent liver tissues more than 50% of
the cells showed positive caspase 3, the AI was not increased as
compared with HCC, no matter ca
spase 3 was positive or negative. This suggests that other factor(s)
may exist in regulating normal cell apoptosis.
p21WAF1
was first reported as a universal inhibitor of cyclin-dependent
kinase, which is required for G1 to S transition[15].
Previous studies demonstrated that p21WAF1 can interrupt
the apoptotic
process at a point upstream from caspase-3 activation, because serum
starvatio
n, which also synchronized cells in G1 but did not induce
p21WAF1, did not protect cells from apoptosis, while
restoring a
late G1 checkpoint by inducing p21WAF1
expression can protect cells
from DNA damage induced apoptosis[16]. p21WAF1
can bind procaspase-3 but not activate caspase 3. On the other hand,
activa
ted caspase 3 can cleave p21WAF1. P21 cleavage by the
activated cpp32 specifically abolished its interaction with PCNA and
may interfere with normal PCNA-dependent repair[15]. The
presence of p21WAF1 in hu
man HCCs was reported previously in our paper[12]. In
this context, the expression of p21WAF1 was also
determined together with caspase 3 in a
n attempt to find whether there is relationship between them. We
found that expression of caspase 3 was strongly associated with p21WAF1
in 16 cases of HCC. There was no significant difference in AI
between p21WAF1(+)/cpp32(+) and p21WAF1(-)
/cpp32(+) (6.98‰
vs 7.21‰). The results indicated that p21WAF1 may be
merely one of
the inhibitors which can reduce caspase 3 mediated cell apoptosis in
HCCs. In fact, some other caspase 3 inhibitors, for example survivin,
were reported to have overexpression in human tumors, including
gastric and colorectal cancer
[17,18]. Survivin is believed to bind activated caspase 3
and further in
hibit cell apoptosis. It was reported that XIAP can interrupt
caspase 3
mediated apoptosis via the same way as p21WAF1. So,
further investig
ation on other caspase 3 regulating protein is needed to find the
regulation mec
hanism of caspase 3 mediated apoptosis in human HCCs.
REFERENCES
1 Tang ZY,Yu YQ,Zhou
XD, Ma ZC, Wu ZQ. Progress and prospects in hepatocellular carcinoma
surgery. Ann Chir,
1998;52:558-563
2 Kokura K, Nakadai T, Kishimoto T, Makino Y,
Muramatsu M, Tamura T. Gene expression in hepatomas. J Gastroenterol
Hepatol,1998;13(Suppl):S132-141
3 Wyllie AH. Apoptosis and carcinogenesis. Europ J
Cell Biology, 1997;73:189-197
4 Kidd VJ. Proteolytic activities that mediate
apoptosis. Annu Rev Physiol, 1998;60:533-573
5 Kitada S, Andersen J, Akar S, Zapata JM,
Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai
K,
Hines
J, Reed JC. Expression of
apoptosis-regulating proteins in chronic lymphocytic leukemia:
correlations with in vitro
and
in vivo chemoresponses.Blood,1998;91: 3379-3389
6 Estrov Z, Thall PF, Talpaz M, Estey EH,
Kantarjian HM, Andreeff M, Harris D, Van Q, Walterscheid M, Kornblau
SM.
Caspase 2 and caspase 3 protein levels as predictors of survival in
acute myelogenous leukemia.Blood,
1998;92:3090-3097
7 Krajewski S, Gascoyne RD, Zapata JM, Krajewska
M, Kitada S, Chhanabhai M, Horsman D, Berean K, Piro LD, Fugier-
Vivier
I, Liu YJ, Wang HG, Reed JC. Immunolocalization of the
ICE/Ced-3-family protease, CPP32 (Caspase-3), in
non-Hodgkin’s lymphomas, chronic lymphocytic leukemias, and reactive lymph
nodes. Blood, 1997;89:3817-3825
8 Chhanabhai M, Krajewski S, Krajewska M, Wang HG,
Reed JC, Gascoyne RD. Immunohistochemical analysis of
interleukin-1
β-converting enzyme/Ced-3 family protease, CPP32/Yama/Caspase-3,
in Hodgkin’s disease. Blood,
1997;90:2451-2455
9 Zapata JM, Krajewska M, Krajewski S, Huang RP,
Takayama S, Wang HG, Adamson E, Reed JC. Expression of multiple
apoptosis-regulatory
genes in human breast cancer cell lines and primary tumors.Breast
Cancer Res
Treat,1998;47:129-140
10 Nakagawara A, Nakamura Y, Ikeda H, Hiwasa T, Kuida K, Su
MS, Zhao H, Cnaan A, Sakiyama S. High levels of
expression
and nuclear localization of interleukin-1 beta converting
enzyme (ICE) and CPP32 in favorable human
neuroblastomas. Cancer Res,1997;57:4578-4584
11 Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M.
Resistance to Fas-mediated apoptosis: activation of caspase 3 is
regulated
by cell cycle regulator p21WAF1 and IAP gene family ILP.Oncogene,
1998;17:931-939
12 Sun BH, Wu ZB, Ruan YB, Yang ML, Liu B. p21WAF1/Cipl gene
expression in primary human hepatocellular carcinoma
and
its relationship with p53 gene mutation.J Tongji Medical University,
1999;19:1-5
13 Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa
N. Inhibition of apoptosis by survivin predicts shorter
survival rates
in colorectal cancer.Cancer Res, 1998;58:5071-5074
14 Krajewska M, Wang HG, Krajewski S, Zapata JM, Shabaik A,
Gascoyne R, Reed JC. Immunohistochemical analysis of in
vivo
patterns of expression of CPP32 (caspase 3), a cell death
protease.Cancer Res,1997;57:1605-1613
15 Li R,Waga S,Hannon GJ,Beach D,Stillman B. Differential
effects by the p21 CDK inhibitor on PCNA dependent DNA
replication and
repair. Nature, 1994;371:534-537
16 Bissonnette N, Hunting DJ. p21-induced cycle arrest in G1
protects cells from apoptosis induced by UV irradiation or
RNA polymerase
Ⅱ
blockage.Oncogene, 1998;16:3461-3469
17 Lu CD, Altieri DC, Tanigawa N. Expression of a novel
antiapoptosis gene, survivin, correlated with tumor cell apoptosis
and p53 accumulation in gastric
carcinomas.Cancer Res, 1998;58:1808-1812
18 LaCasse EC, Baird S, Korneluk RG, Mackenzie AE. The
inhibitors of apoptosis (IAPs)
and their emerging role in cancer.
Oncogene,
1998;17:3247-3259
| |